The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Cone rod dystrophy is a rare inherited retinal disorder impacting cones and rods, leading to progressive vision loss. The market for cone rod dystrophy is poised for growth due to rising disease ...

The gene therapy market for ocular rare diseases is expanding rapidly as breakthroughs in viral vectors (like AAV) and gene-editing tools enable one-time, disease-modifying treatments for previously ...

A recent review published in Genes & Diseases by researchers from the Naval Medical University and the 922nd Hospital of the Joint Service Support Force of the PLA provides a comprehensive overview of ...

The Global Gene Editing Market, valued at USD 4.68 billion in 2023, is poised for transformative growth, projected to expand at a compound annual growth rate (CAGR) of 10.2% through 2033. This dynamic ...